Cardiovascular disease remains a leading cause of morbidity and mortality in people with
types 1 or 2 diabetes mellitus. Although beneficial roles for strict control of hyperglycemia …

There has been an increase in the range of non-insulin anti-hyperglycaemic agents used to
treat type 2 diabetes. With the globally rising rates of type 2 diabetes and complications such …

Purpose The liver regulates lipid metabolism. Decreasing mTOR (mechanistic target of
rapamycin complex 1) and enhancing AMPK (AMP-activated protein kinase) help degrade …

There are significant injuries of pancreatic islets due to obesity and insulin resistance.
Therefore, GLP-1 receptor agonists like Semaglutide might benefit the islet structural …

Elderly patients with diabetes are at high risk of polypharmacy because of multiple
coexisting diseases and syndromes. Polypharmacy increases the risk of drug–drug and …

Background: Cardiovascular morbidity and mortality are a major burden in patients with type
2 diabetic mellitus. In a landmark study, semaglutide (an injectable glucagon like peptide-1 …

Cardiovascular and microvascular disorders are serious complications of diabetes. Intensive
glucose control is believed to hinder the pathological progression of these complications. In …

A 2-es típusú diabetes mellitus korábbi, döntően a glykaemiás kontrollra fókuszáló terápiás
megközelítése helyett a legújabb nemzetközi ajánlások multifaktoriális kezelést preferálnak …